Rethinking Antipsychotic Dosing: Lessons from the RADAR Trial

In this episode, we explore the RADAR trial's findings on antipsychotic dose reduction in schizophrenia. Can patients with chronic schizophrenia safely reduce or discontinue their antipsychotic medications without increasing relapse risk? The trial's results challenge common assumptions about medication reduction and provide crucial guidance for clinical practice.

Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.5 CME: Quick Take Vol. 62
• Antipsychotic Dose Reduction in Schizophrenia: Insights From the RADAR Trial